Pregnancy has surprising ocular ties, some rare, some all too common

Article

The connection between pregnancy and the eyes may not be obvious, but several ocular changes, such as dry eyes or declines in IOP, can occur during pregnancy.

Common ocular changes associated with pregnancy include decreased corneal sensitivity and increased corneal curvature, both of which can contribute to dry eye. Decreased IOP in the third trimester has also been reported and could be a concern for patients with glaucoma, said Dr. Cunningham, director of optometry, Dell Laser Consultants, Austin, TX.

Conditions that can be aggravated during pregnancy include diabetic retinopathy, choroidal hemangioma, and uveitis.

Pregnancy itself is an independent risk factor for diabetic retinopathy. The risk of progression depends mainly on the severity of disease. Women who do not have diabetic retinopathy should be evaluated during the first trimester and thereafter based on symptoms.

Patients with mild retinopathy should be seen once during both the first and second trimesters and monthly during the final trimester. In cases of moderate retinopathy, patients should be evaluated every 4 to 6 weeks throughout their pregnancy. Most progression, however, occurs by the end of the second trimester.

Recent studies have suggested that hypertension might be a useful clinical indicator of risk for progression of diabetes, and optometrists might want to add a blood pressure check to their routine visits with pregnant patients who have diabetic retinopathy, Dr. Cunningham added.

Gestational diabetes is not a risk factor for diabetic retinopathy, although it is for development of type 2 diabetes, Dr. Cunningham said.

Choroidal hemangiomas

Choroidal hemangiomas associated with pregnancy are rare but may occur because of increased pressure on blood vessels. In most cases, they can be safely monitored without treatment, but a hemangioma may induce retinal detachment if it is close to the macula or leaking fluid.

Uveitis is more common in pregnancy but often misdiagnosed or untreated by obstetricians. Recurrence during pregnancy is well established in the literature. The direct relationship is not understood; however, patients often have a preexisting systemic condition such as Behcet's or Vogt-Koyanagi-Harada syndrome. These patients as well as women with a history of uveitis should be counseled about the possibility of a uveitic attack during pregnancy (most likely during the first trimester) or postpartum.

Related: Pediatric glaucoma: types, tests and treatments

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.